Drug discovery is a $250 billion annual endeavor in which 90 percent of candidates fail in clinical trials. Kvantify, a Danish deep tech company based at INCUBA in Aarhus, just closed the second tranche of its EUR 7 million funding round to prove that quantum computing can change those odds. The round was backed by the European Innovation Council Fund (EIC) and Danish venture firm Delphinus Venture Capital.

The investment is modest by Silicon Valley standards but precisely calibrated for a company operating at the intersection of two notoriously capital-intensive fields: quantum computing and pharmaceutical research. Kvantify is not trying to build quantum hardware. It is building the software layer that makes today's imperfect quantum machines useful for the specific, brutal computational challenge of simulating molecular behavior.

If you have ever wondered when quantum computing would stop being a press release and start being a product, Kvantify's answer is: now, for molecular discovery, on real quantum hardware.

The core problem Kvantify addresses is both elegant and maddening. Simulating how molecules behave, how they fold, bind, react, and interact, requires solving quantum mechanical equations. These equations scale exponentially with the number of electrons in the system. A small molecule with 20 atoms can be simulated on a classical supercomputer. A drug-like molecule with 100 atoms cannot, at least not with the accuracy needed to predict whether it will actually work in a human body.

This computational wall is one of the fundamental reasons drug discovery is so expensive and failure-prone. Pharmaceutical companies screen millions of compounds using approximations, then spend billions testing the survivors in clinical trials. Better molecular simulation could identify winners earlier, eliminate losers faster, and dramatically reduce the attrition rates that make drug development one of the riskiest investments in any industry.

Quantum computers, by their very nature, process information using the same quantum mechanical principles that govern molecular behavior. The concept of quantum computing was literally invented to handle this problem. Kvantify's bet is that the hardware has matured enough to start delivering commercial value, if you build the right software.

In November 2025, Kvantify launched Qrunch, its technology for running quantum chemistry calculations on real quantum computers. The platform is not a simulation or a demo. It is a production tool designed to integrate with existing drug discovery workflows, offering pharmaceutical and biotech organizations a way to test quantum-enhanced molecular simulations alongside their classical computational chemistry pipelines.

"We are thrilled to have the EIC Fund and Delphinus on board for this round extension," said Dr. Jorg Weiser, Executive Chairperson at Kvantify. "Their support empowers us to accelerate innovation and strengthens Europe's position in quantum technology."

The EIC Fund's participation is significant beyond the check size. The European Innovation Council is the EU's flagship program for identifying and supporting breakthrough technologies with clear commercialization paths. Its investment in Kvantify suggests that European institutions are moving past the quantum hype cycle and beginning to back companies with working products rather than theoretical roadmaps.

Svetoslava Georgieva, Chair of the EIC Fund Board, said the investment reflects the fund's mission to support "pioneering technologies" that position Europe at the forefront of next-generation innovation. The endorsement matters because it comes from an institution that reviews hundreds of deep tech startups annually and selects only a handful for direct investment.

Denmark, in particular, is building a credible quantum cluster. The country's universities, including the University of Copenhagen and Aarhus University, have produced world-class quantum research. Companies like IQM in Finland and PasQal in France are building the hardware. Kvantify is making the case that Denmark can own the application layer, the software that converts quantum hardware capabilities into commercial outcomes for specific industries.

To understand why Kvantify's timing might be right, consider the economics. The average cost to develop a new drug and bring it to market exceeds $2.6 billion, according to the Tufts Center for the Study of Drug Development. Much of that cost stems from late-stage failures, compounds that looked promising in early screening but failed in human trials because the computational models that predicted their behavior were not accurate enough.

Even a modest improvement in simulation accuracy could save hundreds of millions of dollars per drug program by killing bad candidates earlier. Kvantify does not need to replace classical computational chemistry entirely. It needs to make it incrementally better at the specific molecular problems where quantum advantage is most pronounced, large molecular systems with strong electron correlation effects.

The company's hybrid approach, combining quantum and classical computing resources, is pragmatic. Today's quantum computers are noisy, error-prone, and limited in qubit count. A pure-quantum approach to drug discovery is still years away. But a hybrid approach that uses quantum processors for the specific sub-problems where they excel, while offloading the rest to classical hardware, can deliver value today. That is what Qrunch is designed to do.

The next phase for Kvantify will focus on making Qrunch accessible to pharmaceutical and biotech organizations for real-world testing. The company is building partnerships with drug discovery organizations to validate quantum workflows on current hardware and establish the benchmarks that will define the category.

For a seven-person startup based in a Danish university incubator, the ambition is extraordinary. But quantum computing has always been a field where small teams with deep expertise move faster than large organizations encumbered by legacy infrastructure and institutional caution. Kvantify has the backing of Europe's most selective innovation fund, a production-ready product, and a market that is desperate for better tools. The molecules are waiting to be simulated. The quantum machines are ready. The question is whether Kvantify can build the bridge between them fast enough.